Pegylated Interferon-Alpha-2A
Hepatitis C Virus Infection
Explore 12 assets in Hepatitis C Virus Infection →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01463956CT.gov Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation | — | Completed | — | — | — |
NCT00207311CT.gov Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegylated Interferon-Alpha-2A (this asset) | French National Agency for Research on AIDS and Viral Hepatitis | Approved | B · 62 |
| Veruprevir | AbbVie | P4 | A |
| Daclatasvir | MTI University | P4 | A |
| Glecaprevir | AbbVie | P3 | A |
| Pibrentasvir | AbbVie | P3 | A |
| Velpatasvir | Peking University People's Hospital | P4 | A |
| Ribavirin | Peking University People's Hospital | P4 | A |
| Sofosbuvir | Peking University People's Hospital | P4 | A |
| Ombitasvir | AbbVie | P3 | A |
+42 more in the Hepatitis C Virus Infection cohort
Other indications for Pegylated Interferon-Alpha-2A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fatty Liver Disease | — | P4 | B · 58 |
| Chronic Hepatitis C Virus Infection | — | P4 | CCC · 55 |
| Melanoma | — | P3 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegylated Interferon-Alpha-2A in Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegylated-interferon-alpha-2a-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →